KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) FCF Margin (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of FCF Margin data on record, last reported at 69.08% in Q4 2025.

  • For Q4 2025, FCF Margin fell 1374.0% year-over-year to 69.08%; the TTM value through Dec 2025 reached 118.97%, down 5671.0%, while the annual FY2025 figure was 118.97%, 5671.0% down from the prior year.
  • FCF Margin reached 69.08% in Q4 2025 per AQST's latest filing, up from 98.43% in the prior quarter.
  • Across five years, FCF Margin topped out at 79.16% in Q1 2023 and bottomed at 269.9% in Q1 2025.
  • Average FCF Margin over 5 years is 67.28%, with a median of 73.33% recorded in 2025.
  • Peak YoY movement for FCF Margin: surged 192430bps in 2021, then crashed -18350bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 77.58% in 2021, then soared by 201bps to 78.54% in 2022, then tumbled by -138bps to 30.01% in 2023, then tumbled by -84bps to 55.34% in 2024, then decreased by -25bps to 69.08% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 69.08% in Q4 2025, 98.43% in Q3 2025, and 78.6% in Q2 2025.